Wayne P. Yetter
Mr. Yetter has served as the Chairman of our Board of Directors since July 2010. Mr. Yetter has served as Chairman of the board of directors of ProActive for Patients Media, Inc., an early investment stage physician-to-patient messaging services company, since October 2009 and also served as its Chief Executive Officer from October 2009 to October 2010. From September 2005 through August 2008, Mr. Yetter served as Chief Executive Officer of Verispan, LLC, a healthcare information company serving pharmaceutical and biotechnology companies. From November 2004 through September 2005, Mr. Yetter served as President and Chief Executive Officer of Odyssey Pharmaceuticals, Inc., a specialty pharmaceutical company. Mr. Yetter also founded Biopharm Advisory, LLC, a healthcare industry advisory firm, and served as its President from July 2003 through September 2005. From September 2003 through November 2004, Mr. Yetter served on the Advisory Board of Alterity Partners, a mergers and acquisition advisory firm. Prior to that, Mr. Yetter served as Chairman and Chief Executive Officer of Synavant, Inc., a customer relationship management and marketing services company focused on the pharmaceutical industry, Chief Operating Officer of IMS, President and Chief Executive Officer of Novartis Pharmaceutical Corp., the U.S. division of Novartis AG, and founding President and Chief Executive Officer of Astra Merck Inc. Mr. Yetter also held a variety of management and marketing roles at Merck and Pfizer. Mr. Yetter currently serves on the board of directors of EpiCept Corp., a publicly-traded specialty pharmaceutical company, InfuSystem Holdings, Inc., a publicly-traded provider of infusion pumps and related services, and Strategic Diagnostics Inc., a publicly-traded biotechnology company. Previously, Mr. Yetter also served on the board of directors of the following publicly-traded companies: Noven Pharmaceuticals, Inc., where he was Chairman, Synvista Therapeutics, Inc., Transkaryotic Therapies, Inc., where he was Chairman, Maxim Pharmaceuticals, Inc., and Matria Healthcare, Inc., where he was lead independent director. Mr. Yetter also served on the Executive Committee of PhRMA, the pharmaceutical industry association, from 1997 through 1999. Mr. Yetter holds a BA in biology from Wilkes University and an MBA from Bryant University.
Armando Anido has served as our chief executive officer since July 2012. Mr. Anido has more than 30 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. He is currently a member of the board of directors of Respira Therapeutics, Inc., and was a member of the board of directors of Adolor, until it was sold to Cubist in December 2011. He is the former president and CEO of Auxilium Pharmaceuticals (NASDAQ: AUXL), where under his leadership, sales grew from $42 million in 2005 to more than $260 million in 2011 and market capitalization increased from $200 million to more than $900 million. Prior to Auxilium, Mr. Anido served as executive vice president, sales and marketing, at MedImmune and prior to that, in senior sales and marketing positions at GlaxoWellcome and Lederle Laboratories. At GlaxoWellcome, he was vice president, central nervous system marketing, responsible for the commercialization of the migraine, epilepsy and depression businesses in the U.S. Under his leadership, the migraine business grew to nearly $1 billion in revenues spearheaded by the rapid growth of Imitrex (sumatriptan).
Michael Cola has served as one of our directors since December 2006 and served as Chairman of our Board of Directors from December 2006 through July 2010. From June 2005 to April 2012, Mr. Cola served as President, Specialty Pharmaceuticals at Shire plc, a global specialty pharmaceutical company. Prior to joining Shire, Mr. Cola served as Group President of Safeguard Scientifics, Inc., a holding company for growth stage technology and life sciences companies, and in a variety of positions at AstraZeneca and AstraMerck, including Vice President, Global Clinical Operations. Mr. Cola has also served on the board of directors of Clarient, Inc., a publicly-traded company. Mr. Cola holds a BA in biology and physics from Ursinus College and an MS in biomedical science from Drexel University. Mr. Cola has more than 20 years of international pharmaceutical industry experience.
James A. Datin
James Datin is currently Executive Vice President and Managing Director at Safeguard Scientifics, a growth capital provider to life sciences and technology companies. Mr. Datin brings to the NuPathe board more than 25 years of experience as a successful CEO, who has raised capital for entrepreneurs to grow companies, and has turned around troubled companies throughout the United States, Europe and Asia. At Safeguard, he leverages this expertise to drive partnership opportunities for both life science and technology partner companies, and has earned a multinational track record of success. Prior to Safeguard, Mr. Datin was CEO of Touchpoint Solutions; Group President of Dendrite International; Group Director, Corporate Business Strategy and Planning at GlaxoSmithKline (NYSE:GSK); CEO of Isuta Holdings Berhad; and Director, International Business at Baxter International, Inc. (NYSE:BAX)/Merck KGaA. Mr. Datin currently serves on the board of directors of NovaSom, Putney, Hepatitis B Foundation, and the University City Science Center.
William J. Federici
William J. Federici has served as one of our directors since January 2011. Mr. Federici has served as Vice President and Chief Financial Officer of West Pharmaceutical Services, Inc., a publicly traded global pharmaceutical technology company, since August 2003. From June 2002 until August 2003, he was National Industry Director for Pharmaceuticals of KPMG LLP (accounting firm) and prior thereto, an audit partner with Arthur Andersen, LLP. Mr. Federici is also an Advisory Board Member of the Rutgers University School of Business, and a member of the Board of Trustees at Cancer Care of New Jersey. Mr. Federici holds a BA in Economics and an MBA in Professional Accounting from Rutgers University and is a Certified Public Accountant.
Richard S. Kollender
Richard Kollender is a partner at Quaker Partners, a venture capital and growth equity firm with a focus on the life sciences industry. Prior to joining Quaker Partners in 2003, Mr. Kollender held positions in sales, marketing and worldwide business development at GlaxoSmithKline. He also served as investment manager at S.R. One where he evaluated potential investment opportunities, performed due diligence, structured and negotiated investments and worked with management teams to execute their strategies following investment. Prior to GlaxoSmithKline, Mr. Kollender was a CPA with KPMG Peat Marwick with an emphasis on the healthcare and emerging businesses sectors. Richard currently serves on the board of directors of Insmed (NASDAQ:INSM), Precision Therapeutics, Rapid Micro Biosystems, and Celator Pharmaceuticals. Richard was previously a member of the board of directors of NuPathe from 2007 to 2011.
Robert P. Roche, Jr.
Robert P. Roche, Jr., has served as one of our directors since July 2010. Mr. Roche has served as principal of Robert Roche Associates, LLC, a consulting firm focusing on the pharmaceutical and biotechnology industries, since February 2010. From January 1995 through February 2010, Mr. Roche served as the head of commercial operations at Cephalon, Inc., a global biopharmaceutical company. His most recent position at Cephalon, held from February 2005 through February 2010, was Executive Vice President, Worldwide Pharmaceutical Operations, in which capacity he oversaw several new product launches. Prior to that, Mr. Roche served in a variety of sales and marketing positions at SmithKline Beecham, a global pharmaceutical company. Mr. Roche has served on the board of directors of EKR Therapeutics, a privately-held specialty pharmaceutical company, since November 2011, and on the board of directors of Civitas herapeutics, a privately-held biopharmaceutical company, since January 2012. Previously, Mr. Roche served on the board of directors of LifeCell Corporation, a publicly-traded medical device company focusing on tissue repair products, and from 2008 to 2011, on the board of directors of Intercept Pharmaceuticals, Inc., a privately-held pharmaceutical company focused on metabolic diseases. Mr. Roche currently serves as a Trustee of The Westtown School. Mr. Roche holds a BA in Spanish and history from Colgate University and an MBA from The Wharton School at the University of Pennsylvania.
Brian J. Sisko
Brian Sisko is currently Executive Vice President and Managing Director - Strategy, Development and Operations at Safeguard Scientifics. Mr. Sisko has more than 25 years of experience working with start-up and development-stage companies in various positions, including external legal counsel, internal counsel, executive officer, investor and consultant. Mr. Sisko joined Safeguard as Senior Vice President and General Counsel in August 2007 and became Executive Vice President and Managing Director in November 2012. Prior to joining Safeguard in 2007, he worked with Traffic.com where he was Senior Vice President and General Counsel. Previously, Mr. Sisko was Chief Operating Officer of Halo Technology Holdings. Prior to that, he held a variety of positions in the venture capital and legal fields. Currently, Mr. Sisko serves on the board of directors of AdvantEdge Healthcare Solutions, NovaSom, and Penn Mezzanine.